Victory Capital Management
KNTE

Victory Capital Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Victory Capital Management’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-71,020
Closed -$433K – 2713
2022
Q4 		$433K Sell
71,020
-44,530
-39% -$363K ﹤0.01% 2055
2022
Q3 		$1.38M Sell
115,550
-2,980
-3% -$39K ﹤0.01% 1591
2022
Q2 		$1.5M Buy
118,530
+32,490
+38% +$302K ﹤0.01% 1568
2022
Q1 		$969K Sell
86,040
-30,100
-26% -$331K ﹤0.01% 1832
2021
Q4 		$2.06M Buy
116,140
+20,870
+22% +$440K ﹤0.01% 1546
2021
Q3 		$2.19M Sell
95,270
-770
-0.8% -$16.8K ﹤0.01% 1572
2021
Q2 		$2.24M Sell
96,040
-6,370
-6% -$162K ﹤0.01% 1600
2021
Q1 		$3.19M Sell
102,410
-4,340
-4% -$151K ﹤0.01% 1499
2020
Q4 		$4.25M Buy
+106,750
New +$4.28M ﹤0.01% 1282

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management's KNTE Position: Q1 2023 in Review

Victory Capital Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2023, closing a stake of 71,020 shares — an estimated $433K sold.

Victory Capital Management first reported a position in KNTE in Q4 2020 and held it in 9 quarters. The position peaked at $4.25M in Q4 2020. 71 funds tracked by Wall St. Rank hold KNTE as of Q1 2023.

  • Victory Capital Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Victory Capital Management sold 71,020 Kinnate Biopharma Inc. Common Stock shares in Q1 2023, an estimated $433K.
  • Victory Capital Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 9 quarters.
  • Victory Capital Management's Kinnate Biopharma Inc. Common Stock position peaked at $4.25M in Q4 2020.
  • 71 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2023.

Based on Victory Capital Management's 13F filing for Q1 2023, filed 2 May 2023.